Potential ALS Drug Fails in Study

The AP (5/18) reports, "Teva Pharmaceutical Industries Ltd. said Monday its potential Lou Gehrig's disease treatment," talampanel, "failed to meet a key goal in a midstage study." The drug failed to meet its effectiveness goal in a study of 559 patients, although it did meet its safety goals.